S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ZNTL · Zentalis Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Zentalis Pharmaceuticals Inc (ZNTL)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$2.37
-0.02
(-0.84%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$2.37
$2.34
$2.47
52-WEEK RANGE
$2.37
$1.21
$6.95
What's happening
- ZNTL is down 0.84% today, trading at $2.37. — Live quote
- Volume today (59,837) is well below its 3-month average of 1,263,570. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.59 actual vs. $-0.50 estimated (-18.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 6
Hold 6
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ZNTL
+77.04%
vs S&P 500
+64.26%
1-YEAR RETURN
ZNTL
+54.19%
vs S&P 500
+39.63%
6-MONTH RETURN
ZNTL
-52.39%
3-MONTH RETURN
ZNTL
-52.30%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.59
Est. $-0.50
MISS -18.1%
2026-04-26 (Q1 2026)
$-0.50
Est. $-0.49
MISS -2.9%
2026-01-26 (Q4 2025)
$-0.50
Est. $-0.59
BEAT +15.3%
2025-10-26 (Q3 2025)
$-0.37
Est. $-0.54
BEAT +31.3%
Valuation Measures & Ratios
Enterprise Value4$216.3M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)3.58
Price / Book72.40
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-52.77%
Return on Assets (ROA9)-40.55%
Avg Volume (3M)1,263,570
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $347.2M | $166.2M | $109.6M | $84.3M | $113.9M |
| P/E | -2.65 | -1.21 | -0.77 | -0.41 | -0.68 |
| Price/Sales | — | — | — | — | 2.81 |
| Price/Book | 2.42 | 0.91 | 0.43 | 0.31 | 0.39 |
| EV/Revenue | — | — | — | — | 1.77 |
| EV/EBITDA | -2.13 | -0.88 | -0.43 | — | — |
| ROE | -91.34% | -75.10% | -56.16% | -74.17% | -56.42% |
| ROA | -60.93% | -54.21% | -43.39% | -57.89% | -43.40% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short5,957,612
Change from Prior Settlement+24.47%
% of Float—
Days to Cover (Short Ratio)4.13
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +54.2%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-01; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ZNTL
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $0 | $0 | $40.6M |
| Operating income | -$44.4M | -$37.9M | -$33.7M | -$36.1M | -$45.6M | -$51.4M | -$65.1M | -$24.8M |
| Net income | -$42.3M | -$35.4M | -$26.7M | -$26.9M | -$48.3M | -$40.2M | -$88.3M | $10.1M |
| EPS (diluted) | $-0.59 | $-0.50 | $-0.37 | $-0.37 | $-0.67 | $-0.56 | $-1.24 | $0.14 |
| EPS (basic) | $-0.59 | $-0.50 | $-0.37 | $-0.37 | $-0.67 | $-0.56 | $-1.24 | $0.14 |
| Operating margin | — | — | — | — | — | — | — | -$61 |
| Net margin | — | — | — | — | — | — | — | $25 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $215.3M | $253.1M | $289.0M | $327.2M | $351.7M | $384.0M | $430.3M | $450.7M |
| Total liabilities | $71.7M | $70.4M | $72.8M | $74.4M | $77.2M | $88.6M | $93.2M | $96.3M |
| Stockholders' equity | $143.6M | $182.7M | $216.2M | $252.9M | $274.5M | $295.4M | $337.2M | $354.3M |
| Total current assets | $181.3M | $218.1M | $253.2M | $288.3M | $311.6M | $342.9M | $386.1M | $400.3M |
| Total current liabilities | $37.6M | $35.2M | $36.6M | $37.2M | $39.0M | $49.4M | $52.7M | $54.9M |
| Cash & equivalents | $24.8M | $31.9M | $36.0M | $39.1M | $37.6M | $41.9M | $33.9M | $41.3M |
| Accounts receivable | — | — | $0 | $0 | $0 | $0 | $5.0M | — |
| Property, plant & equipment | $2.5M | $2.7M | $2.8M | $2.9M | $3.1M | $3.2M | $4.7M | $5.0M |
| Goodwill | — | — | — | — | — | — | $0 | $3.7M |
| Intangible assets | — | — | — | — | — | — | — | — |
| Accounts payable | $8.1M | $7.4M | $7.2M | $7.0M | $3.7M | $7.8M | $7.4M | $8.2M |
| Accrued liabilities | $29.5M | $27.9M | $29.4M | $30.1M | $35.3M | $41.7M | $45.3M | $46.7M |
| Other non-current liabilities | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $558.0K | $849.0K | $996.0K |
| Common stock & paid-in capital | $72.0K | $71.0K | $69.0K | $72.0K | $72.0K | $72.0K | $71.0K | $71.0K |
| Retained earnings | -$1.27B | -$1.23B | -$1.19B | -$1.16B | -$1.13B | -$1.10B | -$1.05B | -$1.01B |
| Accumulated other comprehensive income (loss) | -$78.0K | -$50.0K | $196.0K | $186.0K | $59.0K | $358.0K | $558.0K | $1.6M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$37.2M | -$33.0M | -$30.9M | -$27.0M | -$34.7M | -$32.6M | -$39.7M | -$44.0M |
| Investing cash flow | $30.0M | $30.0M | $32.4M | $28.3M | $30.4M | $40.5M | $32.3M | $48.2M |
| Financing cash flow | $65.0K | -$1.1M | -$4.6M | $115.0K | $0 | $189.0K | $0 | $92.0K |
| Free cash flow | -$37.2M | -$33.0M | -$30.9M | -$27.0M | -$34.7M | -$32.6M | -$39.7M | -$44.0M |
| Capital expenditures | $0 | $34.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Depreciation & amortization | $152.0K | $151.0K | $477.0K | $160.0K | $160.0K | $262.0K | $965.0K | $321.0K |
| Share-based compensation | $3.2M | $3.2M | $3.1M | $4.8M | $6.3M | $6.5M | $31.4M | $10.4M |
| Deferred income taxes | — | — | $51.0K | — | — | — | -$63.0K | — |
| Change in accounts receivable | — | — | -$5.0M | — | — | — | $5.0M | — |
| Purchases of investments | $30.0M | $30.0M | $30.2M | $49.5M | $40.2M | $19.5M | $39.2M | $59.2M |
| Sales/maturities of investments | $60.0M | $60.0M | $60.0M | $60.0M | $70.0M | $60.0M | $71.5M | $74.0M |
| Share repurchases | — | — | $10.0M | — | — | — | $0 | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $67.4M | $0 | $0 | — |
| Operating income | -$152.8M | -$191.2M | -$299.5M | -$227.3M | -$216.5M |
| Net income | -$137.1M | -$165.8M | -$292.2M | -$236.8M | -$158.7M |
| EPS (diluted) | $-1.91 | $-2.33 | $-4.47 | $-4.48 | $-3.72 |
| EPS (basic) | $-1.91 | $-2.33 | $-4.47 | $-4.48 | $-3.72 |
| Operating margin | — | -$284 | — | — | — |
| Net margin | — | -$246 | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $289.0M | $430.3M | $551.7M | $539.3M | $454.5M |
| Total liabilities | $72.8M | $93.2M | $114.3M | $105.3M | $90.0M |
| Stockholders' equity | $216.2M | $337.2M | $437.3M | $433.8M | — |
| Total current assets | $253.2M | $386.1M | $496.7M | $451.9M | $350.8M |
| Total current liabilities | $36.6M | $52.7M | $69.4M | $56.6M | $43.9M |
| Cash & equivalents | $36.0M | $33.9M | $28.0M | $43.1M | $59.7M |
| Accounts receivable | $0 | $5.0M | $0 | — | $4.0K |
| Property, plant & equipment | $2.8M | $4.7M | $5.8M | $7.7M | $8.1M |
| Goodwill | — | $0 | $3.7M | $3.7M | $3.7M |
| Accounts payable | $7.2M | $7.4M | $14.9M | $11.2M | $11.6M |
| Accrued liabilities | $29.4M | $45.3M | $54.4M | $45.4M | $32.4M |
| Other non-current liabilities | $500.0K | $849.0K | $1.8M | $2.6M | $0 |
| Common stock & paid-in capital | $69.0K | $71.0K | $70.0K | $59.0K | $45.0K |
| Retained earnings | -$1.19B | -$1.05B | -$888.6M | -$596.4M | -$359.6M |
| Accumulated other comprehensive income (loss) | $196.0K | $558.0K | $2.2M | -$1.4M | -$125.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$125.2M | -$170.9M | -$207.8M | -$163.8M | -$154.1M |
| Investing cash flow | $131.6M | $176.6M | -$44.5M | -$114.2M | -$18.1M |
| Financing cash flow | -$4.3M | $108.0K | $237.3M | $261.0M | $178.5M |
| Free cash flow | -$125.2M | -$171.1M | -$208.4M | -$166.3M | -$160.2M |
| Capital expenditures | $0 | $221.0K | $583.0K | $2.5M | $6.1M |
| Depreciation & amortization | $739.0K | $1.3M | $1.4M | $1.4M | $544.0K |
| Share-based compensation | $20.7M | $67.3M | $54.8M | $46.8M | $35.7M |
| Deferred income taxes | $51.0K | -$63.0K | -$891.0K | -$778.0K | -$858.0K |
| Change in accounts receivable | -$5.0M | $5.0M | $0 | $0 | -$413.0K |
| Purchases of investments | $139.5M | $128.0M | $549.2M | $533.2M | $363.5M |
| Sales/maturities of investments | $250.0M | $271.2M | $505.3M | $421.5M | $365.8M |
| Share repurchases | $10.0M | $0 | $0 | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ZNTL as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-04-30 to 2026-09-30
Recent transactions
- Insiders have net bought 4,335,000 shares over the last 182 days, across 1 purchase and 0 sales.
- Most recent: Bruns Ingmar (Chief Medical Officer) — Grant / award of 9,727 shares on 2026-09-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)4,335,000 sh(1 txns)
Sales (open market)0 sh(0 txns)
Net Shares+4,335,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer | Grant / award | 2026-09-30 | 9,727 |
| WALTERS GROUP | 10% owner | Open market purchase | 2026-08-14 | 4,335,000 |
| Johnson David Michael | Director | Grant / award | 2026-06-16 | 57,100 |
| Skvarka Jan | Director | Grant / award | 2026-06-16 | 57,100 |
| Walker Luke Nathaniel | Director | Grant / award | 2026-06-16 | 57,100 |
| Kariuki Enoch | Director | Grant / award | 2026-06-16 | 57,100 |
| Myers Scott Dunseth | Director | Grant / award | 2026-06-16 | 57,100 |
| Campbell Shannon | Director | Grant / award | 2026-05-26 | 114,200 |
| Vultaggio Vincent | PAO and PFO | Open market sale | 2026-02-10 | 6,894 |
| EASTLAND JULIA MARIE | CEO & President | Open market sale | 2026-02-09 | 889 |
| Matrix Capital Management Company, LP | 10% owner | Open market sale | 2025-12-15 | 7,500,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Bruns Ingmar | Chief Medical Officer | Grant / award | 9,727 | $2.18 |
| 2026-08-14 | WALTERS GROUP | 10% owner | Open market purchase | 4,335,000 | $3.50 |
| 2026-06-16 | Johnson David Michael | Director | Grant / award | 57,100 | $0.00 |
| 2026-06-16 | Skvarka Jan | Director | Grant / award | 57,100 | $0.00 |
| 2026-06-16 | Walker Luke Nathaniel | Director | Grant / award | 57,100 | $0.00 |
| 2026-06-16 | Kariuki Enoch | Director | Grant / award | 57,100 | $0.00 |
| 2026-06-16 | Myers Scott Dunseth | Director | Grant / award | 57,100 | $0.00 |
| 2026-05-26 | Campbell Shannon | Director | Grant / award | 114,200 | $0.00 |
| 2026-02-10 | Vultaggio Vincent | PAO and PFO | Open market sale | 6,894 | $2.42 |
| 2026-02-09 | Bruns Ingmar | Chief Medical Officer | Open market sale | 335 | $2.39 |
| 2026-02-09 | Vultaggio Vincent | PAO and PFO | Open market sale | 3,379 | $2.39 |
| 2026-02-09 | EASTLAND JULIA MARIE | CEO & President | Open market sale | 889 | $2.39 |
| 2026-02-06 | Bruns Ingmar | Chief Medical Officer | Open market sale | 2,962 | $2.43 |
| 2026-02-06 | Vultaggio Vincent | PAO and PFO | Open market sale | 29,951 | $2.43 |
| 2026-02-06 | EASTLAND JULIA MARIE | CEO & President | Open market sale | 7,866 | $2.43 |
| 2026-02-03 | Vultaggio Vincent | PAO and PFO | Open market sale | 556 | $2.52 |
| 2026-02-02 | Vultaggio Vincent | PAO and PFO | Open market sale | 2,540 | $2.55 |
| 2025-12-31 | WALTERS GROUP | 10% owner | Open market purchase | 6,459,973 | $1.20 |
| 2025-12-15 | Matrix Capital Management Company, LP | 10% owner | Open market sale | 7,500,000 | $1.33 |
| 2025-06-17 | Walker Luke Nathaniel | Director | Grant / award | 57,603 | $0.00 |
| 2025-06-17 | Skvarka Jan | Director | Grant / award | 57,603 | $0.00 |
| 2025-06-17 | Johnson David Michael | Director | Grant / award | 57,603 | $0.00 |
| 2025-06-17 | Kariuki Enoch | Director | Grant / award | 57,603 | $0.00 |
| 2025-06-17 | Myers Scott Dunseth | Director | Grant / award | 57,603 | $0.00 |
| 2025-04-30 | Myers Scott Dunseth | Director | Open market purchase | 21,000 | $1.40 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:05 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-06-18 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-18 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-18 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-18 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-18 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-18 | 8-K | 2026-06-16 | View on SEC.gov → |
| 2026-05-27 | 4 | 2026-05-26 | View on SEC.gov → |
Recent news
Headlines about ZNTL (Zentalis Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Zentalis published survival data for Zentalis Pharmaceuticals stock
AD HOC NEWS · 2026-10-21 -
ZNTL Dec 2026 1.000 call (ZNTL261218C00001000) stock price, news, quote and history
Yahoo Finance Singapore · 2026-10-20 -
Zentalis Pharmaceuticals, Inc. Shares Rise After Trial Data Release
www.tokenpost.com · 2026-10-20 -
Zentalis Pharmaceuticals (ZNTL) Shares Rise After Positive Mid-S
GuruFocus · 2026-10-19 -
Zentalis rises as lead asset extends survival in mid-stage trial for ovarian cancer
Seeking Alpha · 2026-10-19 -
Zentalis stock rises on cancer trial data (ZNTL:NASDAQ)
Seeking Alpha · 2026-10-19 -
HC Wainwright & Co. reiterates Buy rating on Zentalis Pharmaceuticals, $10 price target
TradingView · 2026-10-19 -
HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target
Benzinga · 2026-10-19
No headlines in this category right now — try “All”.